Abstract: A method for digital thermal monitoring assessment of vascular function comprising a temporary arterial occlusion using a pneumatic cuff positioned on a subject's upper limb, monitoring skin temperature at the fingertip of the occluded limb for a period of time before, during, and after the occlusion, calculating a Zero Reactivity Curve based on variables including start temperature, room temperature, and the slope of temperature decline during the occlusion, and assessing vascular function based on comparing the Zero Reactivity Curve and the observed temperature rebound after the occlusion is removed.

Abstract: A method for digital thermal monitoring assessment of vascular function comprising a temporary arterial occlusion using a pneumatic cuff positioned on a subject's upper limb, monitoring skin temperature at the fingertip of the occluded limb for a period of time before, during, and after the occlusion, calculating a Zero Reactivity Curve based on variables including start temperature, room temperature, and the slope of temperature decline during the occlusion, and assessing vascular function based on comparing the Zero Reactivity Curve and the observed temperature rebound after the occlusion is removed.

Abstract: A system and method for inducing physiological effects of ischemic conditioning and physiological effects of shear stress in a subject's body that mimic the effect of exercise on the subject. The disclosure includes a first device configured to cause ischemia, a second device configured to mechanically generate arterial shear stress, and a third device configured to monitor one or more of markers of ischemia or hemodynamic parameters and further including a microcontroller and actuators to cause the ischemia for a preset duration and then stop the ischemia for a preset duration, and to repeat the ischemia and reflow periods according to a preset program, simultaneously cause the second device to mechanically generate arterial shear stress according to a preset program of mechanical pulse amplitude, duration, and frequency; and to concurrently monitor hemodynamic parameters or markers of ischemia.

Abstract: A system and method for inducing physiological effects of ischemic conditioning and physiological effects of shear stress in a subject's body that mimic the effect of exercise on the subject. The disclosure includes a first device configured to cause ischemia, a second device configured to mechanically generate arterial shear stress, and a third device configured to monitor one or more of markers of ischemia or hemodynamic parameters and further including a microcontroller and actuators to cause the ischemia for a preset duration and then stop the ischemia for a preset duration, and to repeat the ischemia and reflow periods according to a preset program, simultaneously cause the second device to mechanically generate arterial shear stress according to a preset program of mechanical pulse amplitude, duration, and frequency; and to concurrently monitor hemodynamic parameters or markers of ischemia.

Abstract: Methods and apparatus for blood sampling from skin capillaries are provided. Blood extraction is improved by applying gradient pressure in a proximal to distal direction of an extremity. Blood is extracted and sampled from the skin capillaries with a blood sampling mechanism of at least a lancet and testing kit.

Abstract: The invention relates to an assay for discriminating between Alzheimer's disease (AD) patients, patients with AD-Like disorders that express symptoms like AD, and non-demented age-matched controls (Normal). The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of a group of identified biomarkers, and the biostatistical analysis of the concentration of the identified biomarkers to differentiate patients having AD from Normals and patients having other AD-Like disorders.

Abstract: The invention relates to an assay for discriminating between amyotrophic lateral sclerosis (ALS) patients and patients with ALS-like disorders that express symptoms like ALS. The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of a group of identified biomarkers, and the biostatistical analysis of the concentration of the identified biomarkers to differentiate patients having ALS from patients having other ALS-like disorders.

Abstract: The present invention is an assay for determining if a patient has a neuromuscular disease. The method comprises collecting a biological sample from a patient, separating the proteins present in the biological sample, quantitating a panel of proteins by proteomic techniques, analyzing the quantity of the protein panel using biostatistics, and determining whether or not the patient has a neuromuscular disease based on the statistical analysis of the results.

Abstract: The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of the FK 506-binding protein 7, or prolylisomerase, as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

Abstract: The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of a tripartite motif protein TRIM5 isoform gamma related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

Abstract: The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of an 2?-5?-oligoadenylate synthetase like protein (p59 OASL) related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

Abstract: The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of an acetyl-LDL receptor related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.